OBJECTIVE Tostudytheeffectofmetforminonglucolipidmetabolicdisorderscaused byolanzapineorquetiapineinrats.METHODS Olanzapine1mg·kg-1·d-1wasgivenigorquetiapine 20 mg·kg -1·d -1 was given ig for 4 d,and the dose increased to 40 mg·kg -1·d -1 from the 5th day.Met-formin 100 mg·kg -1·d -1 was given ig from the 15th day.The treatment lasted 8 weeks.Body mass, fasting blood sugar (FBS)and postprandial 2 hours blood glucose (2hPBG)were measured at base-line,3 d,1 week,2 week,4 week,6 week and 8 week.At the end of the 8th week,serum cholesterol (TC),triglyceride (TG),low density lipoprotein (LDL-C),high density lipoprotein (HDL-C),fruc-tosamine(FA)andinsulin(IRS)weremeasured.RESULTS Therewasnosignificantstatisticaldiffer-ence between normal control group and metformin 1 00 mg·kg -1·d -1 group.At the end of the 6th week, compared with normal control group,the body mass and 2hPBG were significantly increased in olanzap-ine 1 mg·kg -1·d -1 group and quetiapine 40 mg·kg -1·d -1 group (P<0.05),respectively.At the end of the 8th week,body mass,2hPBG,INS,FA,TC,TG,LDL-C were significantly increased (P<0.05), and HDL-C decreased in olanzapine group and quetiapine group(P<0.05),respectively.FBS was increased only in olanzapine group(P<0.05).Compared with olanzapine group or quetiapine group, body mass,FBS,2hPBG,INS,FA,TC,TG,LDL-C were significantly decreased by metformin admin-istration(P<0.05).CONCLUSION Metformincaneffectivelypreventandtreatweightgainand glucolipid metabolic disorder caused by olanzapine or quetiapine.

Cytokinesis ; Humans ; Lymphocytes ; pathology ; Micronucleus Tests ; Neoplasms ; genetics ; Risk Factors

OBJECTIVETo evaluate the reliability and validity of SF-36 scale in urban residents, and provide reference for the selection of suitable health measure tools for urban residents.

METHODSMulti-stage cluster stratified sampling was conducted to select the residents aged ≥18 years in three urbanized communities of Hangzhou. SF-36 scale was used for the measurement of the quality of life and Spearman-Brown and Cronbach' s α coefficients were used for the evaluation of split-half reliability and internal consistency reliability. The convergent and discriminative validity were evaluated by using the success rate of experiments and the criterion-related validity was evaluated with correlation analysis and non-parameter test. Structural equation modeling was used in the evaluation of contract validity.

RESULTSSF-36 scale had good split-half reliability (R=0.94) and internal-consistency reliability (except for bodily pain and vitality, Cronbach's α range: 0.70-0.91). The convergent validity (88.57%), discriminate validity (successful rates 90.61%) and the criterion-related validity (γs=0.56, the score was consistent with the self-reported health status) were good. Second-order confirmatory factor analysis model was not well-fitted (GFI= 0.721, AGFI= 0.682, CFI= 0.731, RMR= 0.084, RMSEA= 0.098), indicating that the construct validity was poor.

CONCLUSIONThe reliability, consolidation validity, discrimination validity and criterion-related validity of SF-36 scale were good, while the construct validity was poor. Improvement is needed when the scale is used for urban residents.

Factor Analysis, Statistical ; Health Status ; Humans ; Quality of Life ; Reproducibility of Results ; Self Report ; Surveys and Questionnaires ; Urban Population